Navigation Links
Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control
Date:3/2/2012

egulatory approval of lorcaserin may not be accepted or reviewed, when anticipated, if at all; the timing of regulatory review and approval is uncertain, and the FDA may not complete its review of the lorcaserin NDA resubmission by the PDUFA date; the occurrence, timing and results of FDA advisory committee meetings relating to lorcaserin and other drug candidates; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to lorcaserin and Arena's other research and development programs may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for regulatory review or approval; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014 Research ... "Sensor Market in Consumer Healthcare by Application, Sensor ... to 2013 - 2020" report to their offering. ... There has been an increasing momentum for consumer healthcare ... and sophistication. The consumer healthcare will lessen the healthcare ...
(Date:7/23/2014)... 2014 Research and Markets  has announced ... by Product, End-user & by Lead Type - Global ... http://photos.prnewswire.com/prnh/20130307/600769 The ... major segments, namely, holter monitor, resting, and stress type ... $3,683 million in 2013 and is poised to grow ...
(Date:7/23/2014)... -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, ... OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE ... JURISDICTION. AbbVie (NYSE: ABBV ) will ... 2014, before the market opens. AbbVie will host ... a.m. Central time (9 a.m. Eastern). It will be accessible ...
Breaking Medicine Technology:Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 2Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 3Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3AbbVie to Host Second-Quarter Earnings Conference Call 2AbbVie to Host Second-Quarter Earnings Conference Call 3AbbVie to Host Second-Quarter Earnings Conference Call 4AbbVie to Host Second-Quarter Earnings Conference Call 5AbbVie to Host Second-Quarter Earnings Conference Call 6
... SPRING HARBOR, N.Y., Sept. 1 The ASCO ... Advisory Committee (ODAC) recommendation that the breast cancer indication ... voting members, breast cancer specialists, oncologists in private practice, ... available online now at ASCOPost.com and appear in the ...
... According to Millennium Research Group (MRG), the global authority on ... continue to be used in a narrow set of indications ... grow at a much lower rate than previously expected.  With ... compared to the nonfusion market as a whole which is ...
Cached Medicine Technology:The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer 2The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer 3European Interspinous Process Decompression Device Market Will Grow Nominally at 1.2% over the Next Five Years 2European Interspinous Process Decompression Device Market Will Grow Nominally at 1.2% over the Next Five Years 3
(Date:7/24/2014)... Ft. Lauderdale, FL (PRWEB) July 24, 2014 ... to provide a wide range of pharmaceutical products ... the agreement, BMG member practices can benefit from ... GroupPurchasing Solutions is growing rapidly, building on a ... “Our approach is to offer deep savings on ...
(Date:7/24/2014)... AZ (PRWEB) July 24, 2014 Colleen’s ... has donated $10,000 to Johns Hopkins Medicine to fund ... Billy Cundiff. , According to Cundiff, this is the ... supported ovarian cancer research at Johns Hopkins Medicine. , ... is to work with promising young investigators at some ...
(Date:7/23/2014)... (PRWEB) July 24, 2014 By ... engaging in the dust-collecting equipment in China, including ... of bag-type dust collectors and remaining more than ... electrostatic precipitators. At the end of 2013, the ... China reached CNY 23.65 billion, accounting for 55.94% ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 The beauty ... dollars by the year 2020, according to recent news ... among the top sellers in the U.S. and the ... wrinkle cream under $100 is now reviewed at ... help a first-time or experienced shopper to compare the ...
(Date:7/23/2014)... FL (PRWEB) July 23, 2014 Men ... pay higher premiums for life insurance based on national ... cheap life insurance rates search to its comprehensive tool ... at http://quotespros.com/life-insurance.html . , Providers that are ... selected, sorted and reviewed in one or two clicks. ...
Breaking Medicine News(10 mins):Health News:Seacoast Medical Partners with Blackmaple Group to Provide Members Cost Savings on Wide Range of Pharmaceutical Products 2Health News:Colleen’s Dream Foundation Donates $10,000 to Johns Hopkins Medicine for Ovarian Cancer Research 2Health News:Colleen’s Dream Foundation Donates $10,000 to Johns Hopkins Medicine for Ovarian Cancer Research 3Health News:2018 Dust Collecting Equipment Industry in China Major Enterprises Analysis Now Available at MarketReportsChina.com 2Health News:2018 Dust Collecting Equipment Industry in China Major Enterprises Analysis Now Available at MarketReportsChina.com 3Health News:Best Wrinkle Cream Under $100 Reviewed at Top News Website Online 2Health News:Cheap Life Insurance Rates for Married Couples Added to Search System at Insurer Portal Online 2
... According to new research that will be presented on ... American Academy of Dental Sleep Medicine, the majority of U.S. ... for sleep disorders, which affect more than 70 million adults ... California - Los Angeles (UCLA) School of Dentistry surveyed each ...
... new research that will receive the Graduate Student Research ... Meeting of the American Academy of Dental Sleep Medicine, ... in patients with obstructive sleep apnea (OSA) may help ... advancement splints (MAS) have been shown to be a ...
... ... newest and strongest acrylic walk in tub available. And now clients can purchase this walk in ... ... Beauty Bath collection offers the newest and strongest acrylic walk in tub available. And now clients ...
... ... - Stuyvesant Cove Park 2420 FDR Drive (off East 23rd Street),New York, NY, ... Green Mountain Energy Company will host a special Summer Bash celebration at Solar ... in the fields of clean tech, solar energy, design, fashion, retailing, finance and ...
... Cancer Center at Hackensack University Medical Center announced today ... American Society of Clinical Oncology (ASCO) annual meeting taking ... highlights include a comparison of first-line treatments for an ... a new genetically engineered cancer therapy, and the value ...
... ... to seek solutions for measuring and ultimately eliminating pain , ... Washington, DC (Vocus) June 4, 2010 -- ... Pain Neurobiology Laboratory at the Sheikh Zayed Institute for Pediatric Surgical Innovation. Dr. Quezado ...
Cached Medicine News:Health News:US dental schools leave graduates unprepared to screen for sleep disorders 2Health News:Tongue measurements may help dentists determine oral appliance therapy success for sleep apnea 2Health News:The Walkinbathtub1 Factory After Years in Design Has Released the Most Up to date Acrylic Walk in Tub in the World 2Health News:The Walkinbathtub1 Factory After Years in Design Has Released the Most Up to date Acrylic Walk in Tub in the World 3Health News:Green Drinks NYC and Green Mountain Energy Company Present Summer Bash at Solar One 2Health News:John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting 2Health News:John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting 3Health News:John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting 4Health News:Former NIH Chief Joins Children's National Medical Center 2Health News:Former NIH Chief Joins Children's National Medical Center 3
... The BladderScan BVM 6500 ... noninvasively to determine UEBW ... and bladder volume using ... BVM 6500 was designed ...
... Inflatable Penile Prosthesis (IPP) is ... be surgically implanted into the ... erectile dysfunction (also known as ... patient with voluntary control over ...
... I continues to be a proven, reliable ... I to have mechanical reliability rates of ... implants. ioflex material contributes to excellent mechanical ... because Bioflex: ,Provides maximum, controlled girth expansion ...
... The AMS 700 Series is an advanced three-part ... the abdomen, a pump placed in the scrotum ... corpora cavernosa. It closely simulates the look and ... for innovative penile implant technology, the AMS 700 ...
Medicine Products: